NGS-based RNA-sequencing Market

NGS-based RNA-sequencing Market Size by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, small RNA), End-User, Region - Global Forecast to 2027

Report Code: BT 5297 May, 2023, by marketsandmarkets.com

The global size of NGS-based RNA-sequencing market in terms of revenue was estimated to be worth $2.5 billion in 2022 and is poised to reach $5.5 billion by 2027, growing at a CAGR of 17.2% from 2022 to 2027. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The key factors propelling the growth of this market are the advantages of RNA sequencing over conventional technologies, the decreasing costs of genome sequencing, increasing government funding to support genomics projects, growing research involving RNA sequencing, growing cancer cases, the increasing application of NGS in cancer research, and rapid growth in personalized medicine.

Attractive Opportunities in the NGS-based RNA-sequencing Market

NGS-based RNA-seq Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global NGS-based RNA-sequencing Market Dynamics

DRIVER: Decreasing costs of genome sequencing

In the last two decades, advances in genomics have resulted in a substantial reduction in the cost of genomic sequencing. For example, in 2019, the cost of whole human genome sequencing using Illumina’s technology was USD 1,000, compared to USD 14 million in 2008, and is expected to decline further in 2023. Pacific Biosciences of California provides human genome sequencing 10X coverage at ~USD 3,000 and 30X coverage at ~USD 10,000.

The cost of sequencing depends on the genome size, which varies from organism to organism. For instance, targeted sequencing is less expensive than whole-genome sequencing. Apart from genome size, data quality is another major factor associated with variations in the cost of sequencing. Sequencing cost also depends on the average number of times each base in the genome is actually “read” during the sequencing workflow. Due to the reduced costs, several companies are participating in RNA sequencing projects. The cost per raw megabase of RNA sequence has also declined in the last two decades. This has helped sequencing service providers to offer NGS-based RNA sequencing services at lower prices. Consequently, the application of these services is increasing with their affordability.

RESTRAINT: Standardization concerns of RNA-sequencing in diagnostic testing

A shift from research applications of RNA-sequencing to clinical diagnostic applications is expected due to the decreasing sequencing costs. Hence, there is a need to standardize tests to avoid discrepancies in understanding and studying reports of RNA-sequencing diagnostic applications. The US Food and Drug Administration (FDA) is working to establish regulations for RNA sequencing diagnostics to tackle uncertainties regarding the accuracy and reliability of NGS. The interpretation of RNA-sequencing data requires trained physicians as efficient RNA-sequencing data analysis is a critical factor for diagnosis. However, the complexity of NGS technologies and data presents significant challenges to its acceptance in clinical laboratory practices, quality measures, and compliance with regulatory and professional standards. There is a need to identify unmet gaps and processes for test validation, quality control, and quality assurance of NGS-based RNA-sequencing applications for clinical testing. Thus, the lack of standardization in RNA sequencing for diagnostic testing is expected to hamper the growth of the NGS-based RNA-sequencing market.

OPPORTUNITY: Adoption of blockchain technology and cloud computing

The adoption of blockchain technology in healthcare is still nascent. Still, it has a huge potential to transform the current healthcare industry, revolutionize public and private service delivery, and strengthen customer data transparency. The increasing adoption of Blockchain-as-a-Service (BaaS) with significant funding through venture capitalists and initial coin offerings (ICOs) creates growth opportunities. Companies such as Nebula Genomics (US) are working on projects to share genetic information available to researchers securely, and patients are expected to be paid for shared data. The UK-based EncrypGen did similar work in genomic data storage.

With advancements in life sciences and IT, bioinformatics is witnessing a new trend in cloud technology. Cloud computing can efficiently handle vast quantities of biological data generated by high-throughput experiments. Ongoing efforts in nanopore sequencing technology and cloud technology for bioinformatics involve developing a large variety of services from data storage, data acquisition, and data analysis, and accordingly developing utility-supplied cloud computing services delivered over the internet. Thus, future efforts in developing and commercializing novel services for blockchain and cloud technology are expected to offer growth opportunities in the NGS-based RNA-sequencing market.

CHALLENGE: Storage and interpretation of sequencing data

RNA-sequencing enables the quantitative and qualitative investigation of different RNAs, including microRNAs, messenger RNAs, small interfering RNAs, and long noncoding RNAs. The use of RNA sequencing has increased due to NGS, which yields readouts of billions of bases from a single instrument daily. As this sequencing data accumulates, standardization becomes difficult, due to which downstream computational analysis of RNA sequencing data remains complex and generates an enormous amount of data. The study and interpretation of complex data from NGS platforms pose a significant informatics challenge. The lack of automated methodologies and standardized procedures for analyzing this RNA sequencing data is a major hurdle in data interpretation. Although software solutions for data analysis are available, the demand for more efficient data management facilities has intensified. Furthermore, researchers working daily on these instruments must navigate the information provided by datasets. Hence, new data management tools and sufficient training of skilled professionals pose a major challenge for the NGS industry.

North America accounted for the largest share of the NGS-based RNA-sequencing industry

Geographically, the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America held the dominant share, followed by Europe. North America accounted for the largest share of the global market in 2021 owing to the availability of government support, advancements in RNA sequencing products, the growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in the region. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to a significant focus on R&D, the decreasing costs of NGS products and services, and the increasing focus of major market players on strengthening their presence in the Asia Pacific.

NGS-based RNA-seq Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global NGS-based RNA-sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Eurofins Scientific (UK).

Scope of the NGS-based RNA-sequencing Industry

Report Metrics

Details

Market Revenue in 2022

$2.5 billion

Projected Revenue in 2027

$5.5 billion

Revenue Rate

Poised to grow at a CAGR of 17.2%

Market Driver

Decreasing costs of genome sequencing

Market Opportunity

Adoption of blockchain technology and cloud computing

This report categorizes the NGS-based RNA-sequencing market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Sample Preparation Products
    • By Workflow
      • Library Preparation and Target Enrichment
      • Quality Control
    • By Method
  • RNA-sequencing Platforms and Consumables
  • RNA-sequencing Services
  • Data Analysis, Storage & Management

By Technology

  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Single-molecule Real-time Sequencing
  • Nanopore Sequencing

By Application

  • Expression Profiling Analysis
  • Small RNA-sequencing
  • De Novo Transcriptome Assembly
  • Variant Calling and Transcriptome Epigenetics

By End User

  • Research and Academia
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments of NGS-based RNA-sequencing Industry

  • In July 2022, Illumina Inc. (US) launched Illumina DRAGEN v4.0, an accurate and comprehensive secondary analysis platform.
  • In January 2021, Oxford Nanopore Technologies collaborated with NVIDIA to integrate the NVIDIA DGX Station A100 into Oxford Nanopore’s ultra-high-throughput sequencing system, PromethION.
  • In July 2019, Oxford Nanopore Technologies (UK) launched GridION for real-time, on-demand, long-read, direct DNA or RNA sequencing.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 24)
    1.1 STUDY OBJECTIVES 
    1.2 NGS-BASED RNA-SEQUENCING INDUSTRY DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONAL SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                                FIGURE 2 BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
                    FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 PRODUCT-BASED MARKET ESTIMATION
                    FIGURE 4 PRODUCT-BASED MARKET ESTIMATION
           2.2.2 APPLICATION-BASED MARKET ESTIMATION
                    FIGURE 5 APPLICATION-BASED MARKET ESTIMATION
    2.3 PRIMARY RESEARCH VALIDATION 
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 6 DATA TRIANGULATION
    2.5 STUDY ASSUMPTIONS 
          FIGURE 7 STUDY ASSUMPTIONS
    2.6 RESEARCH LIMITATIONS 
 
3 EXECUTIVE SUMMARY (Page No. - 38)
    FIGURE 8 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 NGS-BASED RNA-SEQUENCING INDUSTRY, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 REGIONAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 42)
    4.1 NGS-BASED RNA-SEQUENCING INDUSTRY OVERVIEW 
          FIGURE 13 GROWING RESEARCH ACTIVITIES INVOLVING RNA-SEQUENCING TO DRIVE MARKET
    4.2 ASIA PACIFIC: MARKET, BY END USER AND COUNTRY (2021) 
          FIGURE 14 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2021
    4.3 GEOGRAPHICAL SNAPSHOT OF MARKET 
          FIGURE 15 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.4 MARKET, BY REGION 
          FIGURE 16 NORTH AMERICA TO DOMINATE MARKET IN 2027
 
5 MARKET OVERVIEW (Page No. - 46)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 NGS-BASED RNA-SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Decreasing costs of genome sequencing
                                FIGURE 18 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2021
                    5.2.1.2 Advantages of RNA-sequencing over conventional technologies
                    5.2.1.3 Increasing government funding to support genomics projects
                    5.2.1.4 Growing research involving RNA-sequencing
                    5.2.1.5 Rising cancer cases and increasing applications of NGS in cancer research
                                TABLE 1 CANCER INCIDENCE, 2020 VS. 2040
                    5.2.1.6 Rapid growth in personalized medicine adoption
           5.2.2 RESTRAINTS
                    5.2.2.1 Lack of qualified specialists
                    5.2.2.2 End-user budget constraints in developing countries
                    5.2.2.3 Standardization concerns of RNA-sequencing in diagnostic testing
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Adoption of blockchain technology and cloud computing
           5.2.4 CHALLENGES
                    5.2.4.1 Storage and interpretation of sequencing data
                    5.2.4.2 Analysis of RNA-sequencing data to detect novel transcripts
                    5.2.4.3 Ethical issues and challenges in testing procedure
 
6 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE (Page No. - 55)
    6.1 INTRODUCTION 
          TABLE 2 NGS-BASED RNA-SEQUENCING INDUSTRY, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
    6.2 RNA-SEQUENCING PLATFORMS & CONSUMABLES 
           6.2.1 INCREASING AVAILABILITY OF PLATFORMS AND GROWING CONSUMABLE USAGE TO ENSURE GROWTH
                    TABLE 3 RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 4 NORTH AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 5 EUROPE: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 6 ASIA PACIFIC: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 7 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3 SAMPLE PREPARATION PRODUCTS 
           6.3.1 SAMPLE PREPARATION TO BE FIRST STEP OF NGS WORKFLOW
                    TABLE 8 SAMPLE PREPARATION PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 9 NORTH AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 10 EUROPE: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 11 ASIA PACIFIC: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 12 LATIN AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.2 SAMPLE PREPARATION PRODUCTS, BY WORKFLOW
                    6.3.2.1 Library preparation & target enrichment
                    6.3.2.2 Quality control
           6.3.3 SAMPLE PREPARATION PRODUCTS, BY METHOD
                    6.3.3.1 Manual sample preparation
                    6.3.3.2 Microfluidic sample preparation
                    6.3.3.3 Robotic liquid handling sample preparation
    6.4 RNA-SEQUENCING SERVICES 
           6.4.1 INCREASING ADOPTION OF ADVANCED INFRASTRUCTURE AND EXPERTISE AMONG END USERS TO DRIVE DEMAND
                    TABLE 13 RNA-SEQUENCING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 14 NORTH AMERICA: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 15 EUROPE: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 16 ASIA PACIFIC: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 17 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 DATA ANALYSIS, STORAGE & MANAGEMENT 
           6.5.1 INTEGRATION OF CLOUD COMPUTING AND BIOINFORMATICS TO PROPEL MARKET
                    TABLE 18 DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 19 NORTH AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 20 EUROPE: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 21 ASIA PACIFIC: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 22 LATIN AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY (Page No. - 69)
    7.1 INTRODUCTION 
          TABLE 23 NGS-BASED RNA-SEQUENCING INDUSTRY, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    7.2 SEQUENCING BY SYNTHESIS 
           7.2.1 SBS TECHNOLOGY TO ENABLE HIGHEST PRODUCTION OF BASE PAIRS WITHIN SHORTEST TIME
                    TABLE 24 SEQUENCING BY SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 25 NORTH AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 26 EUROPE: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 27 ASIA PACIFIC: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 28 LATIN AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 ION SEMICONDUCTOR SEQUENCING 
           7.3.1 ION SEMICONDUCTOR SEQUENCING PLATFORMS TO POSSESS HIGH-THROUGHPUT CAPABILITIES
                    TABLE 29 ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 30 NORTH AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 31 EUROPE: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 32 ASIA PACIFIC: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 33 LATIN AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING 
           7.4.1 SMRT SEQUENCING TO PRODUCE RESULTS IN SHORTER TIME AND LOWER COSTS
                    TABLE 34 SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 35 NORTH AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 36 EUROPE: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 37 ASIA PACIFIC: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 38 LATIN AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 NANOPORE SEQUENCING 
           7.5.1 NANOPORE SEQUENCING TO POSSESS DIRECT RNA-SEQUENCING CAPABILITIES
                    TABLE 39 NANOPORE SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 40 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 41 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 42 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 43 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION (Page No. - 83)
    8.1 INTRODUCTION 
          TABLE 44 NGS-BASED RNA-SEQUENCING INDUSTRY, BY APPLICATION, 2020–2027 (USD MILLION)
    8.2 EXPRESSION PROFILING ANALYSIS 
           8.2.1 INCREASING NEED FOR IMPROVED PROGNOSIS OF PATIENTS TO PROPEL MARKET
                    TABLE 45 EXPRESSION PROFILING ANALYSIS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 46 NORTH AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 47 EUROPE: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 48 ASIA PACIFIC: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 49 LATIN AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 SMALL RNA-SEQUENCING 
           8.3.1 RISING NEED FOR ACCURATE DIAGNOSTIC ANALYSIS TO SUPPORT MARKET
                    TABLE 50 SMALL RNA-SEQUENCING MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 51 NORTH AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 52 EUROPE: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 54 LATIN AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 DE NOVO TRANSCRIPTOME ASSEMBLY 
           8.4.1 INCREASING CANCER CASES TO DRIVE SEGMENT
                    TABLE 55 DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 56 NORTH AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 57 EUROPE: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 58 ASIA PACIFIC: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 59 LATIN AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS 
           8.5.1 COMPLICATED RNA SEQUENCE DATA ANALYSIS TO RESTRAIN SEGMENT
                    TABLE 60 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 61 NORTH AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 62 EUROPE: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 63 ASIA PACIFIC: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 64 LATIN AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 NGS-BASED RNA-SEQUENCING MARKET, BY END USER (Page No. - 96)
    9.1 INTRODUCTION 
          TABLE 65 NGS-BASED RNA-SEQUENCING INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
    9.2 RESEARCH & ACADEMIA 
           9.2.1 INCREASING COLLABORATIONS WITH NGS PLAYERS AND RISING GOVERNMENT FUNDING TO PROPEL MARKET
                    TABLE 66 MARKET FOR RESEARCH & ACADEMIA, BY REGION, 2020–2027 (USD MILLION)
    9.3 HOSPITALS & CLINICS 
           9.3.1 INCREASING ADOPTION OF NGS SYSTEMS TO DRIVE MARKET
                    TABLE 67 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
    9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.4.1 CONSOLIDATION WITH NGS PLAYERS FOR TARGET THERAPIES TO PROPEL MARKET
                    TABLE 68 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 69 MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
 
10 NGS-BASED RNA-SEQUENCING MARKET, BY REGION (Page No. - 102)
     10.1 INTRODUCTION 
             TABLE 70 NGS-BASED RNA-SEQUENCING INDUSTRY, BY REGION, 2020–2027(USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT
             TABLE 71 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
             TABLE 72 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
             TABLE 73 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
             TABLE 74 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             TABLE 75 NORTH AMERICA: NGS-BASED RNA-SEQUENCING INDUSTRY, BY END USER, 2020–2027(USD MILLION)
             10.2.1 US
                        10.2.1.1 Favorable funding scenario and growing R&D activity to drive market
                                      TABLE 76 US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 77 US: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 78 US: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Government initiatives for genome research to boost market
                                      TABLE 79 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 80 CANADA: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 81 CANADA: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
     10.3 EUROPE 
             TABLE 82 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020–2027(USD MILLION)
             TABLE 83 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
             TABLE 84 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
             TABLE 85 EUROPE: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             TABLE 86 EUROPE: MARKET, BY END USER, 2020–2027(USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany to dominate European market during forecast period
                                      TABLE 87 GERMANY: NGS-BASED RNA-SEQUENCING INDUSTRY, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 88 GERMANY: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 89 GERMANY: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.3.2 UK
                        10.3.2.1 Strong presence of NGS organizations and their initiatives to stimulate market
                                      TABLE 90 UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 91 UK: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 92 UK: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Growing awareness of high-throughput sequencing in genetic characterization to accelerate growth
                                      TABLE 93 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 94 FRANCE: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 95 FRANCE: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.3.4 REST OF EUROPE
                        TABLE 96 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                        TABLE 97 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                        TABLE 98 REST OF EUROPE: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT
             TABLE 99 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING INDUSTRY, BY COUNTRY, 2020–2027(USD MILLION)
             TABLE 100 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
             TABLE 101 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
             TABLE 102 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             TABLE 103 ASIA PACIFIC: MARKET, BY END USER, 2020–2027(USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Established players and favorable government initiatives to drive market
                                      TABLE 104 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 105 CHINA: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 106 CHINA: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Growing awareness and rising incidence of genetic disorders to propel market
                                      TABLE 107 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 108 JAPAN: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 109 JAPAN: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising interest of companies for collaborations to drive market
                                      TABLE 110 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 111 INDIA: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 112 INDIA: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 113 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                        TABLE 114 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                        TABLE 115 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
     10.5 LATIN AMERICA 
             TABLE 116 LATIN AMERICA: NGS-BASED RNA-SEQUENCING INDUSTRY, BY COUNTRY, 2020–2027(USD MILLION)
             TABLE 117 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
             TABLE 118 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
             TABLE 119 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             TABLE 120 LATIN AMERICA: MARKET, BY END USER, 2020–2027(USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 High HIV prevalence to drive demand for NGS in research
                                      TABLE 121 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 122 BRAZIL: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 123 BRAZIL: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Economic growth and support for infrastructural development to propel market
                                      TABLE 124 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                                      TABLE 125 MEXICO: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                                      TABLE 126 MEXICO: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                        TABLE 127 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING INDUSTRY, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                        TABLE 128 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                        TABLE 129 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 LACK OF INFRASTRUCTURE TO RESTRAIN MARKET
                        TABLE 130 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020–2027(USD MILLION)
                        TABLE 131 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2020–2027(USD MILLION)
                        TABLE 132 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027(USD MILLION)
                        TABLE 133 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027(USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 143)
     11.1 OVERVIEW 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 21 KEY DEVELOPMENTS IN NGS-BASED RNA-SEQUENCING INDUSTRY, 2019–2022
     11.3 MARKET SHARE ANALYSIS 
             FIGURE 22 NGS-BASED RNA-SEQUENCING INDUSTRY SHARE, BY KEY PLAYER, 2021
             TABLE 134 NGS-BASED RNA-SEQUENCING INDUSTRY: DEGREE OF COMPETITION
     11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
     11.5 COMPETITIVE LEADERSHIP MAPPING 
             11.5.1 TERMINOLOGY/NOMENCLATURE
                        11.5.1.1 Visionary leaders
                        11.5.1.2 Innovators
                        11.5.1.3 Dynamic differentiators
                        11.5.1.4 Emerging companies
                                      FIGURE 24 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (OVERALL MARKET)
                                      FIGURE 25 NGS-BASED RNA-SEQUENCING INDUSTRY, COMPETITIVE LEADERSHIP MAPPING, 2021 (SMES/START-UPS)
     11.6 COMPETITIVE SCENARIO 
             TABLE 135 NGS-BASED RNA-SEQUENCING INDUSTRY: PRODUCT/SERVICE LAUNCHES
             TABLE 136 NGS-BASED RNA-SEQUENCING MARKET: DEALS
             TABLE 137 NGS-BASED RNA-SEQUENCING INDUSTRY: OTHER DEVELOPMENTS
 
12 COMPANY PROFILES (Page No. - 151)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     12.1 KEY PLAYERS 
             12.1.1 ILLUMINA, INC.
                        TABLE 138 ILLUMINA, INC.: COMPANY OVERVIEW
                        FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT, 2021
                        TABLE 139 ILLUMINA, INC.: PRODUCT LAUNCHES
                        TABLE 140 ILLUMINA, INC.: DEALS
                        TABLE 141 ILLUMINA, INC.: OTHER DEVELOPMENTS
             12.1.2 QIAGEN N.V.
                        TABLE 142 QIAGEN N.V.: COMPANY OVERVIEW
                        FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT, 2021
                        TABLE 143 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS
                        TABLE 144 QIAGEN N.V.: DEALS
             12.1.3 PERKINELMER, INC.
                        TABLE 145 PERKINELMER, INC.: COMPANY OVERVIEW
                        FIGURE 28 PERKINELMER, INC.: COMPANY SNAPSHOT, 2021
                        TABLE 146 PERKINELMER, INC.: PRODUCT LAUNCHES
             12.1.4 EUROFINS SCIENTIFIC
                        TABLE 147 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
                        FIGURE 29 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT, 2021
                        TABLE 148 EUROFINS SCIENTIFIC: DEALS
             12.1.5 OXFORD NANOPORE TECHNOLOGIES
                        TABLE 149 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW
                        TABLE 150 OXFORD NANOPORE TECHNOLOGIES: PRODUCT LAUNCHES
                        TABLE 151 OXFORD NANOPORE TECHNOLOGIES: DEALS
                        TABLE 152 OXFORD NANOPORE TECHNOLOGIES: OTHER DEVELOPMENTS
             12.1.6 AGILENT TECHNOLOGIES, INC.
                        TABLE 153 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2021
             12.1.7 BGI GROUP
                        TABLE 154 BGI GROUP: COMPANY OVERVIEW
                        TABLE 155 BGI GROUP: DEALS
             12.1.8 GENEWIZ (PART OF BROOKS AUTOMATION)
                        TABLE 156 GENEWIZ: COMPANY OVERVIEW
                        TABLE 157 GENEWIZ: SERVICES LAUNCHED
             12.1.9 HAMILTON COMPANY
                        TABLE 158 HAMILTON COMPANY: COMPANY OVERVIEW
             12.1.10 NUGEN TECHNOLOGIES (PART OF TECAN TRADING AG)
                        TABLE 159 NUGEN TECHNOLOGIES: COMPANY OVERVIEW
             12.1.11 PSOMAGEN (FORMERLY KNOWN AS MACROGEN)
                        TABLE 160 PSOMAGEN: COMPANY OVERVIEW
             12.1.12 F. HOFFMANN-LA ROCHE AG
                        TABLE 161 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
                        FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT, 2021
                        TABLE 162 F. HOFFMANN-LA ROCHE AG: DEALS
             12.1.13 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 163 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
                        FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT, 2021
                        TABLE 164 THERMO FISHER SCIENTIFIC, INC.: DEALS
             12.1.14 TAKARA BIO, INC.
                        TABLE 165 TAKARA BIO, INC.: COMPANY OVERVIEW
                        FIGURE 33 TAKARA BIO, INC.: COMPANY SNAPSHOT, 2021
             12.1.15 PACIFIC BIOSCIENCES
                        TABLE 166 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
                        FIGURE 34 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT, 2021
     12.2 OTHER PLAYERS 
             12.2.1 ZYMO RESEARCH
             12.2.2 LUCIGEN CORPORATION
             12.2.3 GENOTYPIC TECHNOLOGY
             12.2.4 OXFORD GENE TECHNOLOGY (PART OF SYSMEX)
             12.2.5 BECTON, DICKINSON AND COMPANY
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 201)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 AVAILABLE CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the NGS-based RNA-sequencing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the NGS-based RNA-sequencing market. The secondary sources used for this study include the National Institutes of Health (NIH), the Biotechnology and Biological Science Research Council (BBSRC), GLOBOCAN, the Department of Biotechnology (DBT), National Human Genome Research Institute (NHGRI), The RNA Society, European Molecular Biology Laboratory (EMBL), World Bank, United States Food and Drug Administration (US FDA), Eurostat, Statistics Canada, Factiva, ScienceDirect, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements, research journals, press releases, and trade and business professional associations, among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Following is a breakdown of the primary respondents:

NGS-based RNA-seq Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the NGS-based RNA-sequencing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the NGS-based RNA-sequencing business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global NGS-based RNA-sequencing market based on product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the overall NGS-based RNA-sequencing market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • To strategically profile the key players and comprehensively analyze their product & service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product and service launches, expansions, and R&D activities in the NGS-based RNA-sequencing market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 5297
Published ON
May, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the NGS-based RNA-sequencing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
knowledgestore logo

Hold On!

Want to explore hidden markets that can drive new revenue in NGS-based RNA-sequencing Market?

Find Hidden Markets
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback